Danaher plans unveiling at ADLM 2026
July 28, 2026—At ADLM 2026, Danaher companies will come together to unveil the next generation of diagnostic innovation.
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 28, 2026—At ADLM 2026, Danaher companies will come together to unveil the next generation of diagnostic innovation.
July 27, 2026—Pictor Holdings is debuting at ADLM 2026 its next-generation high-resolution platform, the PictImager, for research use only.
July 27, 2026—Seegene has released findings from an analysis of approximately 260,000 pediatric respiratory PCR test results collected over 42 months from children aged zero to five years.
July 27, 2026—Siemens Healthineers has launched capillary testing on the Atellica CH, IM, and CI analyzers after receiving the CE mark for 24 capillary blood testing claims.
July 24, 2026—ARUP Laboratories has launched the ARUP Clarispect Multiple Myeloma MRD by Spectral Flow Cytometry.
July 23, 2026—Seegene USA has received FDA emergency use authorization for the Allplex HSV-1&2/VZV/MPXV assay.
July 22, 2026—Cepheid will unveil the third generation of the GeneXpert system on Tuesday, July 28, at the Association for Diagnostics and Laboratory Medicine Annual Scientific Meeting.
July 21, 2026—The Florida Society of Pathologists 5th Multidisciplinary Interactive Precision Medicine Symposium will take place Aug. 22 at Moffitt Cancer Center, 12902 USF Magnolia Drive, in Tampa, Fla.
July 20, 2026—Zepto Life Technology has introduced FungiFlex Pneumocystis jirovecii, a targeted plasma cell-free DNA liquid biopsy assay for the detection of P. jirovecii, and the FungiFlex Mold Plus panel, which combines invasive mold detection with P. jirovecii in a single plasma-based test order.
July 15, 2026—Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products, a global developer and manufacturer of anatomic pathology products, from Linden Capital Partners and Audax Private Equity. Following the closing, StatLab will become part of Leica Biosystems. StatLab provides a broad portfolio of products across the preanalytical and analytical histology workflow, from specimen collection and tissue processing through slide preparation and staining. Built on a strong reputation for